Table 1.
Characteristics of invasive breast cancer patients and control participants from Detroit and Los Angeles components of the Women’s CARE Study
| Overall | Detroit | Los Angeles | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Controls (n = 2012) | Cases (n = 1195) | P-value1 | Controls (n = 771) | Cases(n = 361) | P-value1 | Controls (n = 1241) | Cases (n = 834) | P-value1 | |
| Race | |||||||||
| White | 57.1% | 56.6% | 0.77 | 57.7% | 62.1% | 0.17 | 56.7% | 54.2% | 0.26 |
| Black | 42.9% | 43.4% | 42.3% | 38.0% | 43.3% | 45.8% | |||
| Education | |||||||||
| ≤High school | 40.0% | 35.9% | 0.01 | 46.2% | 44.9% | 0.54 | 36.2% | 32.0% | 0.05 |
| Technical school or some college | 33.7% | 38.7% | 30.1% | 33.2% | 35.9% | 41.0% | |||
| College graduate | 26.3% | 25.4% | 23.7% | 21.9% | 27.9% | 27.0% | |||
| Mean age at reference date (SD), years | 48.9 (8.4) | 49.0 (8.6) | 0.672 | 49.0 (8.5) | 48.7 (8.8) | 0.562 | 48.8 (8.4) | 49.1 (8.5) | 0.352 |
| First-degree breast cancer family history | 8.2% | 15.6% | <0.0001 | 9.3% | 17.2% | 0.0001 | 7.5% | 14.9% | <0.0001 |
| Age at menarche, years | |||||||||
| ≤11 | 28.5% | 25.6% | 0.17 | 29.3% | 26.6% | 0.70 | 28.0% | 25.2% | 0.31 |
| 12 | 25.9% | 27.2% | 25.4% | 26.6% | 26.2% | 27.5% | |||
| 13 | 25.6% | 28.2% | 26.1% | 28.5% | 25.3% | 28.1% | |||
| ≥14 | 20.0% | 19.0% | 19.2% | 18.3% | 20.6% | 19.3% | |||
| Number of full-term (>26 week) pregnancies | |||||||||
| Never pregnant | 8.8% | 11.2% | 0.02 | 8.3% | 10.0% | 0.91 | 9.0% | 11.8% | 0.02 |
| Only non-full-term pregnancy | 7.9% | 7.2% | 5.1% | 5.3% | 9.6% | 8.0% | |||
| 1 | 15.6% | 17.9% | 15.7% | 17.2% | 15.6% | 18.2% | |||
| 2 | 28.5% | 29.6% | 29.4% | 28.0% | 28.0% | 30.3% | |||
| 3 | 19.4% | 17.3% | 19.8% | 19.1% | 19.1% | 16.6% | |||
| ≥4 | 19.9% | 16.7% | 21.7% | 20.5% | 18.8% | 15.1% | |||
| Menopausal status | |||||||||
| Premenopausal | 46.2% | 48.6% | 0.12 | 46.0% | 49.3% | 0.12 | 46.3% | 48.3% | 0.21 |
| Postmenopausal | |||||||||
| Never HT use | 15.5% | 15.9% | 17.6% | 21.3% | 14.1% | 13.6% | |||
| Ever HT use | 25.8% | 25.7% | 24.1% | 19.7% | 26.9% | 28.3% | |||
| Unknown | 12.5% | 9.8% | 12.2% | 9.7% | 12.7% | 9.8% | |||
| Mean body mass index 5 years before reference date (SD), years | 26.1 (6.0) | 26.0 (5.8) | 0.882 | 26.2 (6.1) | 26.1 (6.0) | 0.662 | 26.0 (6.0) | 26.0 (5.7) | 0.842 |
| Duration of oral contraceptive use, years | |||||||||
| Never | 20.3% | 21.2% | 0.84 | 17.9% | 23.3% | 0.18 | 21.8% | 20.3% | 0.78 |
| <1 | 17.7% | 17.7% | 16.6% | 15.2% | 18.5% | 18.8% | |||
| 1–4 | 26.8% | 26.6% | 28.4% | 29.9% | 25.9% | 25.2% | |||
| 5–9 | 19.7% | 18.2% | 21.7% | 18.0% | 18.5% | 18.4% | |||
| ≥10 | 15.5% | 16.2% | 15.4% | 13.6% | 15.5% | 17.4% | |||
| ER | |||||||||
| Negative | 42.0% | 44.0% | 41.1% | ||||||
| Positive | 58.0% | 56.0% | 58.9% | ||||||
| PR | |||||||||
| Negative | 44.6% | 46.5% | 43.8% | ||||||
| Positive | 55.4% | 53.5% | 56.2% | ||||||
| HER2 | |||||||||
| Negative | 81.9% | 84.8% | 80.7% | ||||||
| Positive | 18.1% | 15.2% | 19.3% | ||||||
| P53 | |||||||||
| Negative | 72.1% | 80.6% | 68.4% | ||||||
| Positive | 27.9% | 19.4% | 31.6% | ||||||
SD, standard deviation.
1
P-value ascertained from Pearson χ2 test, except where otherwise noted.
2
P-value from nonparametric Wilcoxon tests.